Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia

References

• Kaiser AB, Zhang N, Van Der Pluijm W. Global prevalence of type 2 diabetes over the next ten years (2018–2028). Poster #202-LB. Poster presented at the: American Diabetes Association; 2018:67.
   Google Scholar
• Al Dawish MA, Robert AA, Braham R, et al. Diabetes mellitus in saudi arabia: a review of the recent literature. Curr Diabetes Rev. 2016;12(4):359–368. doi:10.2174/1573399811666150724095130
   PubMedGoogle Scholar
• Meo SA. Prevalence and future prediction of type 2 diabetes mellitus in the Kingdom of Saudi Arabia: a systematic review of published studies. J Pak Med Assoc. 2016;66(6):722–725.
   PubMed Web of Science ®Google Scholar
• Al Slail FY, Abid O, Assiri AM, Memish ZA, Ali MK. Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. J Epidemiol Glob Health. 2016;6(1):29–36. doi:10.1016/j.jegh.2015.07.004
   Google Scholar
• IMS Institute for Healthcare Informatics. Improving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia. Parsippany, NJ; 2016.
   Google Scholar
• Alzaheb RA, Altemani AH. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes. 2018;11:15–21. doi:10.2147/DMSO.S156214
   PubMed Web of Science ®Google Scholar
• Gordon J, McEwan P, Idris I, Evans M, Puelles J. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care. 2018;6(1):e000512. doi:10.1136/bmjdrc-2018-000512
   PubMed Web of Science ®Google Scholar
• Khayyat SM, Mohamed MMA, Khayyat SMS, et al. Association between medication adherence and quality of life of patients with diabetes and hypertension attending primary care clinics: a cross-sectional survey. Qual Life Res. 2019;28(4):1053–1061. doi:10.1007/s11136-018-2060-8
   Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi:10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498.
   PubMed Web of Science ®Google Scholar
• Schaller M, Sigurgeirsson B, Sarkany M. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. Mycoses. 2017;60(12):800–807. doi:10.1111/myc.12676
   PubMed Web of Science ®Google Scholar
• Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health. 2004;7(2):204–215. doi:10.1111/j.1524-4733.2004.72252.x
   PubMed Web of Science ®Google Scholar
• Shingler SL, Bennett BM, Cramer JA, Towse A, Twelves C, Lloyd AJ. Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin. 2014;30(11):2329–2341. doi:10.1185/03007995.2014.952715
   PubMed Web of Science ®Google Scholar
• Boye KS, Stein D, Matza LS, et al. Timing of GLP-1 receptor agonist initiation for treatment of type 2 diabetes in the UK. Drugs R D. 2019;19(2):213–225. doi:10.1007/s40268-019-0273-0
   Web of Science ®Google Scholar
• Okemah J, Peng J, Quinones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735–1745. doi:10.1007/s12325-018-0819-5
   PubMed Web of Science ®Google Scholar
• Batais MA, Schantter P. Prevalence of unwillingness to use insulin therapy and its associated attitudes amongst patients with type 2 diabetes in Saudi Arabia. Prim Care Diabetes. 2016;10(6):415–424. doi:10.1016/j.pcd.2016.05.007
   Web of Science ®Google Scholar
• Matza LS, Boye KS, Stewart KD, et al. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: a crossover study (PREFER). Diabetes Obes Metab. 2020;22(3):355–364.
   Web of Science ®Google Scholar
• Boye KS, Matza LS, Stewart KD, et al. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J Med Econ. 2019;22(8):806–813. doi:10.1080/13696998.2019.1609482
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy (New York). 1996;37(1):53–72. doi:10.1016/0168-8510(96)00822-6
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol a new facility for the measurement of health related quality of life. Health Policy (New York). 1990;16(3):199–208. doi:10.1016/0168-8510(90)90421-9
   PubMed Web of Science ®Google Scholar
• Kind P. The EuroQol Instrument: an index of health related quality of life. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, Pennsylvania: Lippincott Raven Publishers; 1996:191–201.
   Google Scholar
• Rabin R, Gudex C, Selai C, Herdman M. From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. Value Health. 2014;17(1):70–76. doi:10.1016/j.jval.2013.10.006
   PubMed Web of Science ®Google Scholar
• Hayes RP, DeLozier AM. Reliability, validity, and responsiveness of the Impact of Weight on Self-Perceptions Questionnaire (IW-SP) in individuals with type 2 diabetes and obesity. Diabetes Technol Ther. 2015;17(3):210–214. doi:10.1089/dia.2014.0142
   Web of Science ®Google Scholar
• Zhu L, Lui KJ. Prescott tests of equality in binary data under a three-treatment three-period crossover design. J Biopharm Stat. 2017;27(5):834–844. doi:10.1080/10543406.2016.1269785
   PubMed Web of Science ®Google Scholar
• Balkhi B, Alwhaibi M, Alqahtani N, et al. Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2019;9(7):e029280. doi:10.1136/bmjopen-2019-029280
   Web of Science ®Google Scholar
• Alyami M, Serlachius A, Mokhtar I, Broadbent E. Illness perceptions, HbA1c, and adherence in type 2 diabetes in Saudi Arabia. Patient Prefer Adherence. 2019;13:1839–1850. doi:10.2147/PPA.S228670
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205–218.
   PubMed Web of Science ®Google Scholar
• Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes. 2017;8(4):120–129. doi:10.4239/wjd.v8.i4.120
   PubMed Web of Science ®Google Scholar
• International Diabetes. Federation and the DAR International Alliance. Diabetes and Ramadan: practical Guidelines. April, 2016. Available from: www.idf.org/guidelines/diabetes-in-ramadan andwww.daralliance.org. Accessed October 17, 2020.
   Google Scholar
• Al-Balhan E, Khabbache H, Laaziz A, et al. To fast or not to fast during the month of Ramadan? A comprehensive survey on religious beliefs and practices among Moroccan diabetic patients. Diabetes Metab Syndr Obes. 2018;11:633–640. doi:10.2147/DMSO.S171990
   PubMed Web of Science ®Google Scholar
• Abid M, Hsairi M, Elleuch M, Ben Aissa E. Survey on diabetic patients treated with insulin during the fasting month of Ramadan. Int J Gen Med. 2018;11:33–40. doi:10.2147/IJGM.S131308
   Web of Science ®Google Scholar
• Jabbar A, Hassanein M, Beshyah SA, Boye KS, Yu M, Babineaux SM. CREED study: hypoglycaemia during Ramadan in individuals with type 2 diabetes mellitus from three continents. Diabetes Res Clin Pract. 2017;132:19–26. doi:10.1016/j.diabres.2017.07.014
   Web of Science ®Google Scholar
• Gelhorn HL, Bacci ED, Poon JL, Boye KS, Suzuki S, Babineaux SM. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan. Patient Prefer Adherence. 2016;10:1337–1348. doi:10.2147/PPA.S109289
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Poon JL, Davies EW, Paczkowski R, Curtis SE, Boye KS. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK. Patient Prefer Adherence. 2015;9:1611–1622. doi:10.2147/PPA.S90842
   PubMed Web of Science ®Google Scholar
• Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med. 2011;31(1):19–23. doi:10.4103/0256-4947.75773
   PubMed Web of Science ®Google Scholar